Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242074 | 0.80 | SCD (0.82) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL241052 | 0.80 | SCD (0.82) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL242657 | 0.79 | SCD (1.00) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL243486 | 0.78 | SCD (0.77) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL244959 | 0.78 | SCD (0.77) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL1909686 | 0.77 | RAB9A (0.61) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL244209 | 0.77 | SCD (0.76) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL347629 | 0.76 | SCD (0.60) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL347282 | 0.76 | SCD (0.60) | SCDRAB9APOLBKDM4ELMNA | |
| SCHEMBL244783 | 0.76 | SCD (0.93) | SCDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 4305/4885POLB 2337/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885RAB9A 4305/4885POLB 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.